Network Response to the COVID-19 Pandemic

The safety of our Network members, study participants, and surrounding communities is always our top priority. The HPTN Leadership Team has been monitoring updates and recommendations from the U.S. Centers for Disease Control and Prevention, the World Health Organization and numerous other health-based sources regarding the COVID-19 pandemic. Based on the current guidance, we have committed to the following action steps:

1. No new studies will start at this time.
2. Observational studies will pause until further notice.
3. All screening and enrollments in ongoing studies will pause until further notice.
4. Follow-up will continue for participants currently enrolled in other HPTN studies, with guidance from protocol teams.

We continue to monitor the situation and may adjust our plans as needed.

Click here for more guidance and resource documents on COVID-19.
Annual Meeting Update

The 2020 HPTN Annual Meeting has been postponed due to the COVID-19 pandemic. The meeting is expected to be held in Fall 2020 or later, dependent upon the outcome of the pandemic response. We will share relevant updates via email and the Annual Meeting webpage.

CROI

HPTN researchers virtually presented 14 abstracts showcasing HPTN 052, HPTN 071, HPTN 075, HPTN 078, and the HPTN Modelling Center and HPTN Laboratory Center's ongoing work at the 27th annual Conference on Retroviruses and Opportunistic Infections (CROI).
Biostatistics professor and clinical trials expert Dr. Tom Fleming (middle) joined by the 2019-2020 HPTN Scholars. (L-R) Elzette Rousseau Jemwa, Rogers Sekabira, Dr. Anita Marais, Dr. Derek Dangerfield II, Dr. Rodman Turpin, and Dr. S. Raquel Ramos

Application materials for the HPTN Scholars Program are now available for early-career minority investigators wishing to collaborate with HPTN scientists in the development and implementation of our HIV prevention research agenda. More than fifty (50) scholars have participated in the program since it started in 2010. The 18-month funding period covers a portion of each scholars’ time and includes travel and supplies.

To be considered, domestic applicants must be investigators who have received their terminal degree (e.g., MD, PhD, etc.). For international applicants, current MD, PhD, and MBChB students may apply, along with individuals who have already graduated with their terminal degree.

The HPTN Scholars program is sponsored by the U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Mental Health, and the U.S. National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.
Leo Perelis, a member of the HPTN 083 Community Working Group, is a community educator at the Hospital Ramos Mejía in Buenos Aires, Argentina. Since 1992 he has worked with people living with HIV and supported multiple HPTN, HVTN and IMPAACT studies, as well as the Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) trial.

**How did you first get involved with the HPTN?**

In 2015, HPTN LOC staff invited me to attend an HPTN meeting and I was impressed by the high level of participation from the HPTN Community Advisory Board members. Community Advisory Board members.

**Read More**

**Awareness Days**

**APRIL 10 IS YOUTH AIDS AWARENESS DAY**

**YOUTHAIDSDAY.ORG #NYHAAD**


What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at news@hptn.org.

Copyright © 2020 The HIV Prevention Trials Network, All rights reserved.